130 related articles for article (PubMed ID: 28256701)
1. Treatment of multiple synchronous misdiagnosed renal cell cancers in a young patient affected by a "de novo" Von Hippel-Lindau syndrome.
Allasia M; Battaglia A; Pasini B; Gazzera C; Calandri M; Bosio A; Gontero P; Destefanis P
Urologia; 2017 Feb; ():0. PubMed ID: 28256701
[TBL] [Abstract][Full Text] [Related]
2. Radiofrequency Ablation for Renal Cancer in Von Hippel-Lindau Syndrome Patients: A Prospective Cohort Analysis.
Allasia M; Soria F; Battaglia A; Gazzera C; Calandri M; Caprino MP; Lucatello B; Velrti A; Maccario M; Pasini B; Bosio A; Gontero P; Destefanis P
Clin Genitourin Cancer; 2017 Aug; ():. PubMed ID: 28866246
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes.
Park BK; Kim CK; Park SY; Shen SH
Acta Radiol; 2013 May; 54(4):418-27. PubMed ID: 23446745
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
5. Multimodal image-guided ablation on management of renal cancer in Von-Hippel-Lindau syndrome patients from 2004 to 2021 at a specialist centre: A longitudinal observational study.
Chan VW; Lenton J; Smith J; Jagdev S; Ralph C; Vasudev N; Bhattarai S; Lewington A; Kimuli M; Cartledge J; Wah TM
Eur J Surg Oncol; 2022 Mar; 48(3):672-679. PubMed ID: 34728141
[TBL] [Abstract][Full Text] [Related]
6. Repeat Percutaneous Radiofrequency Ablation of T1 Renal Cell Carcinomas is Safe in Patients with Von Hippel-Lindau Disease.
Wessendorf J; König A; Heers H; Mahnken AH
Cardiovasc Intervent Radiol; 2021 Dec; 44(12):2022-2025. PubMed ID: 34414496
[TBL] [Abstract][Full Text] [Related]
7. Von Hippel-Lindau and myotonic dystrophy of Steinert along with pancreatic neuroendocrine tumor and renal clear cell carcinomal neoplasm: Case report and review of the literature.
Addeo A; Bini R; Viora T; Bonaccorsi L; Leli R
Int J Surg Case Rep; 2013; 4(8):648-50. PubMed ID: 23774333
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous microwave ablation on management of hereditary renal cell carcinoma in Von Hippel-Lindau disease.
Chen J; Zheng L; Zhang W; Wang Z; Yu J; Liang P
Int J Hyperthermia; 2024; 41(1):2308079. PubMed ID: 38346873
[TBL] [Abstract][Full Text] [Related]
9. Invasive management of renal cell carcinoma in von Hippel-Lindau disease.
Carrion DM; Linares-Espinós E; Ríos González E; Bazán AA; Alvarez-Maestro M; Martinez-Pineiro L
Cent European J Urol; 2020; 73(2):167-172. PubMed ID: 32782836
[TBL] [Abstract][Full Text] [Related]
10. De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.
Ding X; Zhang C; Frerich JM; Germanwala A; Yang C; Lonser RR; Mao Y; Zhuang Z; Zhang M
J Neurosurg; 2014 Aug; 121(2):384-386. PubMed ID: 24678776
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of renal cell carcinoma in Korean patients with von Hippel-Lindau disease compared to sporadic bilateral or multifocal renal cell carcinoma.
Kim WT; Ham WS; Ju HJ; Lee JS; Lee JS; Choi YD
J Korean Med Sci; 2009 Dec; 24(6):1145-9. PubMed ID: 19949673
[TBL] [Abstract][Full Text] [Related]
12. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
13. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract][Full Text] [Related]
14. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
15. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review.
Choi KH; Yu YD; Kang MH; Park DS
Can Urol Assoc J; 2015; 9(9-10):E651-3. PubMed ID: 26425233
[TBL] [Abstract][Full Text] [Related]
17. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis.
Akcaglar S; Yavascaoglu I; Vuruskan H; Oktay B
Int Urol Nephrol; 2008; 40(3):615-20. PubMed ID: 18074239
[TBL] [Abstract][Full Text] [Related]
18. Renal cancer in von Hippel-Lindau disease and related syndromes.
Bausch B; Jilg C; Gläsker S; Vortmeyer A; Lützen N; Anton A; Eng C; Neumann HP
Nat Rev Nephrol; 2013 Sep; 9(9):529-38. PubMed ID: 23897319
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
20. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
